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Volume 57, Number 1 Abstracts 289ultrasound imaging at 1 year, 10 patients have no follow-up data (three of
whom surgery was recently completed, seven of which were lost to follow-
up), and eight patients experienced thrombosis. Stents extended into the
inferior vena cava crossing the normal contralateral side in 45 of 66 patients
(68%). Seven of these patients (15%) suffered new thrombosis of the
nonstented contralateral side. Three of these seven patients were totally
noncompliant with their postoperative anticoagulation; thus, 8% of compli-
ant patients had new contralateral thrombosis after stenting across a normal
contralateral common iliac vein and into the vena caval wall.
Conclusions: To date, there is no consensus whether to stent across
the thrombosed common iliac vein into the cava or completely across and
into the vena cava. From these data it appears that stenting across the
iliocaval confluence can result in a small percentage of contralateral throm-
bosis despite chronic therapeutic anticoagulation. This data will help us
move forward in the development of new technologies and in the treatment
of these patients.
Surgical Reconstruction of the Cephalic Arch for the Management of
Dysfunctional Brachiocephalic Arteriovenous Fistulas
Javier E. Anaya-Ayala, MD, Nader Zamani, BS, Nyla Ismail, PhD, Tony Lu,
MD, Cassidy Duran, MD, Hosam F. El-Sayed, MD, Mark G. Davies, MD,
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Center, Houston, Tex
Objectives:Development of recalcitrant stenotic lesions of the cephalic
arch is a common failure mode of brachiocephalic arteriovenous fistulas.
Endovascular treatment is the first line of therapy for cephalic arch stenosis.
Suboptimal outcomes have led to exploration of surgical alternatives. We
evaluated our initial experience with a cephalic arch reconstruction to salvage
malfunctioning brachiocephalic arteriovenous fistulas (AVFs).
Methods: We retrospectively reviewed all patients requiring surgical
revision of compromised brachiocephalic AVFs due to cephalic arch stenosis.
Percutaneous interventions had failed in all patients, and they underwent
cephalic arch reconstruction (CAR) for salvage. Indications, clinical consid-
erations, and surgical technique were studied; initial patency, complications
and reinterventions were reviewed.
Results: From April 2011 to July 2012, 15 patients (54% women, mean
age 55 22 years) underwent CAR. Stenotic lesions of the cephalic arch at the
confluence with the axillary vein were confirmed by contrast venography. The
average number of percutaneous interventions prior to the decision toCARwas
three (range, 2-7).The time fromaccess creation to cephalic arch reconstruction
was 33 months. Surgical approach involved revisions of the cephalic arch to
redirect the flow as a direct reconnection to the axillary or as a turndown
procedure to the brachial vein in the axilla. Technical success was 100%: all
patients were able to use successfully their access for dialysis after the procedure.
Two patients (13%) required angioplasty of the CAR due to restenosis, another
patient required evacuation of hematoma in postoperative day 14. At a mean of
12 months of follow-up, all AVFs remain functional.
Conclusions: The initial experience with cephalic arch reconstruction
demonstrates that is an effective surgical option to salvage brachiocephalic
AVFs with excellent short-term and functional results (Fig).
Transarterial Treatment of Congenital Renal Arteriovenous Fistulas
Naiem Nassiri, MD, Hirra Ali, MD, Alfio Carroccio, MD, Robert J. Rosen,
MD. Lenox Hill Heart & Vascular Institute of New York, New York, NY
Objectives: Congenital renal arteriovenous fistulas (CRAVFs) repre-
sent a distinct and often misdiagnosed clinical entity with characteristic
hemodynamic and angiographic features. Treatment is warranted given
potential for growth with renal and hemodynamic compromise. We report
our experience with a series of treated symptomatic CRAVFs.
Fig.Methods: During a 10-year period, patients treated for symptomatic
CRAVFs (no history of predisposing renal pathology, instrumentation,
a
eeoplasm, or trauma) were retrospectively investigated for clinical presenta-
ion, radiographic features, treatment outcomes, and complications. A tech-
ically successful treatment included successful delivery of an embolic agent
ith complete obliteration of the fistula. Clinical success included resolution
f symptoms and freedom from recurrence and reintervention. Renal paren-
hymal loss as demonstrated by postembolization angiography was catego-
ized as 0%, 25%, 25% to 50%, or 50%.
Results: Twenty-five patients (8 women) were referred with a pre-
umptive diagnosis of intraparenchymal renal artery aneurysm. Of these, 10
ad true intrarenal aneurysms, three had angiomyolipomas, and 12 had
RAVFs (mean age, 54 years; range 29-71 years). Presenting symptoms
ncluded gross hematuria (n  8), refractory hypertension (diastolic blood
ressure 90 mm Hg despite 3 medications; n  6), flank pain (n  8),
igh-output state (featuring tachycardia and jugular venous distention; n 
), and flank bruit (n  1). Defining angiographic features included a
igh-flow arteriovenous fistula fed by a single, enlarged intrarenal branch
hunting into a dilated vein, occasionally featuring a calcified rim (n 4). All
atients underwent transarterial embolization with coils (n  5), coils and
-butylcyanoacrylate (n  3), detachable balloons (n  2), or Amplatzer
lugs (n 2). Technical success was 100%. Hematuria, tachycardia, jugular
enous distention, pain, and bruit resolved in all. Hypertension improved in
our of six patients (required one medication after embolization). Compli-
ations included a transient, self-limited postprocedural flank discomfort in
ine patients. Parenchymal loss was limited to 25% and occurred in five
atients. There were no recurrences or reinterventions at a mean follow-up
f 55 months (range, 5-96 months). There was one death at 8 years’
ollow-up from intercurrent coronary disease in a patient without high-
utput state.
Conclusions: CRAVF is a rare and likely underdiagnosed clinical
ntity. With greater awareness and accurate diagnosis, effective and durable
ransarterial treatment can be safely performed (Fig).
actors Associated With Primary Vein Graft Thrombosis in a Multi-
enter Trial With Mandated Ultrasound Surveillance
awrence B. Oresanya, MD,1 Gregory L. Moneta, MD,2 Michael Belkin,
D,3 Michael S. Conte, MD1. 1University of California San Francisco, San
rancisco, Calif; 2Oregon Health and Science University, Portland, Ore;
Brigham and Women’s Hospital, Boston, Mass
Objectives: The benefits of preventing lower extremity vein bypass
raft (LEVBG) occlusion through duplex ultrasound (DUS) surveillance
nd timely reintervention are established. However, even in the setting of
urveillance, a significant number of LEVBG become occluded as a first
vent. We sought to identify factors that may contribute to these primary
cclusions using a multicenter clinical trial database.
Methods: This was a retrospective analysis of the PREVENT III
ohort of 1404 patients with critical limb ischemia who underwent LEVBG.
articipants were followed up with DUS at regular intervals (1, 3, 6, 9, and
2 months), with reintervention based on prespecified DUS criteria. Pa-
ients who had graft occlusion as the initial graft-related event were identi-
ed, and technical failures (adjudicated) were excluded.Multivariate analysis
as used to identify predictors of primary graft occlusion.
Results: Primary graft occlusion occurred in 200 participants (14%),
Fig.ccounting for 34% of all initial graft-related events. Primary occlusion
vents were distributed throughout the postoperative year. Rates of recur-
